Saturday, January 26, 2008

Results of the studies showed.

Results of the studies showed that use of tacrolimus and cyclosporine yielded similar action rates at 12 and 18 months, respectively (93.5% for tacrolimus vs 86.1% for cyclosporine at 12 months; 91.7% for tacrolimus vs 89.8% for cyclosporine at 18 months).


Tacrolimus is linked to risks for neurotoxicity, renal social function stultification, contagion, and posttransplant diabetes mellitus. As with most regimens such as this, use of tacrolimus-based immunosuppression is also linked to an increased risk for malignancies, particularly nonmelanoma skin cancers.


The recommended starting oral dose of tacrolimus in center surgical process recipients is 0.075 mg/kg/day (in divided doses 12 time period apart), initiated no sooner than 6 time period posttransplantation. Dosing should be titrated based on clinical assessments of deed and tolerability, and nonessential therapy with corticosteroids is recommended during early posttransplantation.

No comments: